Resonance Health LtdASX: RHT

Liver Fibrosis Device - Clinical Trial Results - Webinar

· Issued by Resonance Health Ltd via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Resonance Health Ltd has announced a webinar to present preliminary results from its MRI Liver Fibrosis Device clinical trial. The trial aims to demonstrate the device's capability to identify liver fibrosis non-invasively, which is crucial for managing liver disease. The webinar will be hosted by the company's MD and CEO, along with the Chief Scientific Officer, and is scheduled for a specific date and time. This announcement highlights the importance of early identification of liver fibrosis and the advantages of non-invasive methods over traditional biopsies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/liver-fibrosis-device-clinical-trial-results-webinar

Release

ASX Announcement – 20 October 202 6 MRI LIVER FIBROSIS DEVICE EPoC CLINICAL TRIAL PRELIMINARY RESULTS WEBINAR Resonance Health Ltd (Resonance or Company) (ASX: RHT) expects to release the preliminary results of its Non-invasive MRI Liver Fibrosis Medical Device extended-proof-of concept (EPoC)...

Resonance Health Ltd on 6ix

Story so far

Earlier from Resonance Health

Later from Resonance Health

All Resonance Health news releases